Status:
COMPLETED
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
Lead Sponsor:
Gwen McMillin
Conditions:
Venous Thromboembolism
Bleeding
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Several human genes affect how medications are metabolized by the body. It is believed that knowledge of variations of these genes can help health care providers better manage an anticoagulation medic...
Detailed Description
This study was completed in 2008 and was published. Consult the citation link for more details.
Eligibility Criteria
Inclusion
- Participants were otherwise healthy adults (≥ 18 years of age) who were planning total hip or knee replacement or revision surgery at the University of Utah Hospital, and scheduled a pre-operative office visit at the University of Utah Orthopaedic Center.
Exclusion
- Blood transfusion in previous two weeks
- Participant is already taking warfarin
- Pre-operative INR \> 4.0
- Pre-operative bilirubin \> 2.4 mg/dL
- Current active cancer diagnosis with ongoing treatment
- Concomitant medications known to exert a major interaction with warfarin such as septra, metronidazole, tramadol, amiodarone, ciprofloxacin, or cimetidine.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT00634907
Start Date
September 1 2006
End Date
October 1 2008
Last Update
June 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah Health Care
Salt Lake City, Utah, United States, 84132